Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Health and Economic After-effects in Leicester Tuberculosis Cohort (HEAL-TB)

16. November 2026 aktualisiert von: University of Leicester

Quantifying the Short to Long-term Physical, Psychological, and Socioeconomic Consequences of Pulmonary and Extra-pulmonary Tuberculosis in Patients in Leicester: a Longitudinal Cohort Study.

HEAL-TB (Health and Economic After-effects in Leicester Tuberculosis cohort) is a prospective observational study examining recovery among adults with pulmonary and extrapulmonary tuberculosis (TB). The study aims to understand how physical health, mental health, quality of life, daily activity, work and economic wellbeing change during TB treatment and up to 12 months after treatment completion.

Participants may join the study at different stages, from diagnosis until six months after completing TB treatment, and will be followed prospectively until 12 months after treatment completion. The study uses questionnaires, lung function testing, the Incremental Shuttle Walk Test, wrist-worn activity monitoring and information collected during routine clinical care. No experimental treatment is provided and participants continue to receive their usual NHS care.

The study aims to describe recovery over time, compare recovery following pulmonary and extrapulmonary TB, and identify factors associated with persistent health problems or poorer recovery.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Detaillierte Beschreibung

HEAL-TB is a single-centre prospective observational cohort study designed to characterise physical, psychological and socioeconomic recovery among adults with pulmonary and extrapulmonary tuberculosis. Participants may enter the cohort at different stages of the tuberculosis pathway, from diagnosis or early treatment until six months after treatment completion, and complete the assessments applicable from their point of enrolment onwards. Follow-up continues until 12 months after treatment completion.

The study combines patient-reported outcome measures with objective assessments of physical function and routinely collected clinical information. Outcomes include health-related quality of life, mental health, work productivity and socioeconomic wellbeing, perceived recovery, lung function, functional exercise capacity, physical activity, sedentary behaviour and sleep. Relevant clinical records, imaging reports and routine investigation results are also reviewed to provide information on disease severity, treatment, complications and recovery.

The study is primarily descriptive and exploratory. Recovery trajectories will be characterised over time, with exploratory comparisons between pulmonary and extrapulmonary tuberculosis. Clinical and disease-related characteristics will also be explored as potential predictors of persistent impairment and poorer recovery. The study is intended to improve understanding of recovery beyond treatment completion and inform future approaches to follow-up, rehabilitation and supportive care for people affected by tuberculosis.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

100

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

16 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Adults with pulmonary or extrapulmonary tuberculosis receiving care or follow-up through University Hospitals of Leicester NHS Trust. Participants may enter the cohort at different stages of the tuberculosis treatment and recovery pathway, from diagnosis until six months after treatment completion. Participants will be recruited through the UHL clinical tuberculosis service across Leicester Royal Infirmary, Glenfield Hospital and Leicester General Hospital and followed prospectively from enrolment until the applicable final assessment at 12 months after treatment completion.

Beschreibung

Inclusion Criteria:

  • Aged 16 years or above.
  • Any sex/gender.
  • Pulmonary or extrapulmonary tuberculosis, receiving or having recently completed tuberculosis treatment, with tuberculosis care or follow-up provided through University Hospitals of Leicester NHS Trust. The latest entry point into the cohort is six months after treatment completion.
  • Willing and able to provide informed consent to participate in the study.

Exclusion Criteria:

  • Expected to move out of the area or unable to attend follow-up visits.
  • Prisoners or people under custodial care.
  • Currently involved in research or recently involved in other research.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Pulmonary Tuberculosis

Participants with pulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study.

Extrapulmonary Tuberculosis

Participants with extrapulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Health-related quality of life measured by EQ-5D-5L
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion

Health-related quality of life assessed using the EQ-5D-5L, including the EQ-5D-5L utility index and EQ Visual Analogue Scale (EQ VAS). Repeated measurements will be used to characterise changes in health-related quality of life during tuberculosis treatment and recovery.

Study entry and applicable follow-up assessments through 12 months after treatment completion
Depressive symptoms measured by PHQ-9
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion

Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery.

Study entry and applicable follow-up assessments through 12 months after treatment completion
Anxiety symptoms measured by GAD-7
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion

Anxiety symptoms assessed using the Generalized Anxiety Disorder-7 (GAD-7) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery.

Study entry and applicable follow-up assessments through 12 months after treatment completion
Lung function measured by spirometry
Zeitfenster: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face

Pre-bronchodilator spirometry including FEV1, FVC, FEV1/FVC ratio and percent predicted values. Repeated measurements will be used to characterise lung-function trajectories during recovery.

Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
Physical activity measured by wrist-worn activity monitor
Zeitfenster: Study entry and applicable follow-up assessments through 6 months after treatment completion

Wrist-worn activity monitoring over 7 days to measure daily physical activity, including steps per day and time spent sedentary and in different physical activity intensity levels.

Study entry and applicable follow-up assessments through 6 months after treatment completion
Work productivity and activity impairment measured by WPAI
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion

Work Productivity and Activity Impairment questionnaire assessing work time missed, impairment while working, overall work impairment and activity impairment. Repeated measurements will characterise changes in work productivity and activity during treatment and recovery.

Study entry and applicable follow-up assessments through 12 months after treatment completion

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Functional exercise capacity measured by Incremental Shuttle Walk Test
Zeitfenster: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face

Functional exercise capacity assessed using the Incremental Shuttle Walk Test (ISWT), with total distance walked recorded in metres.

Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
Respiratory-specific quality of life measured by St George's Respiratory Questionnaire
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion

Respiratory health status assessed using the St George's Respiratory Questionnaire in participants with pulmonary tuberculosis only, measuring respiratory symptoms, activity limitation and psychosocial impacts.

Study entry and applicable follow-up assessments through 12 months after treatment completion
Participant-reported recovery from tuberculosis
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion

Study-specific questions assessing whether participants consider themselves fully recovered from tuberculosis and how their perceived recovery has changed since the previous study visit.

Study entry and applicable follow-up assessments through 12 months after treatment completion

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Mitarbeiter

Ermittler

  • Hauptermittler: Manish Pareek, University of Leicester

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Januar 2027

Primärer Abschluss (Geschätzt)

31. Oktober 2028

Studienabschluss (Geschätzt)

1. April 2029

Studienanmeldedaten

Zuerst eingereicht

16. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

16. November 2026

Zuerst gepostet (Tatsächlich)

20. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 1107
  • 223512/Z/21/Z (Andere Zuschuss-/Finanzierungsnummer: Wellcome Trust)
  • 365242 (Andere Kennung: IRAS)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

There is currently no plan to make individual participant-level data publicly available. Study findings will be disseminated in aggregate form.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren